JP2024091656A5 - - Google Patents

Download PDF

Info

Publication number
JP2024091656A5
JP2024091656A5 JP2024059450A JP2024059450A JP2024091656A5 JP 2024091656 A5 JP2024091656 A5 JP 2024091656A5 JP 2024059450 A JP2024059450 A JP 2024059450A JP 2024059450 A JP2024059450 A JP 2024059450A JP 2024091656 A5 JP2024091656 A5 JP 2024091656A5
Authority
JP
Japan
Prior art keywords
antibody molecule
virus
seq
antibody
ctla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024059450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024091656A (ja
JP7681151B2 (ja
Filing date
Publication date
Priority claimed from EP18192311.1A external-priority patent/EP3617230A1/en
Application filed filed Critical
Publication of JP2024091656A publication Critical patent/JP2024091656A/ja
Publication of JP2024091656A5 publication Critical patent/JP2024091656A5/ja
Application granted granted Critical
Publication of JP7681151B2 publication Critical patent/JP7681151B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024059450A 2018-09-03 2024-04-02 新規抗体およびヌクレオチド配列、ならびにそれらの使用 Active JP7681151B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18192311.1A EP3617230A1 (en) 2018-09-03 2018-09-03 Novel antibodies and nucleotide sequences, and uses thereof
EP18192311.1 2018-09-03
PCT/EP2019/073488 WO2020049001A1 (en) 2018-09-03 2019-09-03 Novel antibodies and nucleotide sequences, and uses thereof
JP2021512914A JP7515461B2 (ja) 2018-09-03 2019-09-03 新規抗体およびヌクレオチド配列、ならびにそれらの使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021512914A Division JP7515461B2 (ja) 2018-09-03 2019-09-03 新規抗体およびヌクレオチド配列、ならびにそれらの使用

Publications (3)

Publication Number Publication Date
JP2024091656A JP2024091656A (ja) 2024-07-05
JP2024091656A5 true JP2024091656A5 (enExample) 2024-12-09
JP7681151B2 JP7681151B2 (ja) 2025-05-21

Family

ID=63490358

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021512914A Active JP7515461B2 (ja) 2018-09-03 2019-09-03 新規抗体およびヌクレオチド配列、ならびにそれらの使用
JP2024059450A Active JP7681151B2 (ja) 2018-09-03 2024-04-02 新規抗体およびヌクレオチド配列、ならびにそれらの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021512914A Active JP7515461B2 (ja) 2018-09-03 2019-09-03 新規抗体およびヌクレオチド配列、ならびにそれらの使用

Country Status (11)

Country Link
US (2) US12291569B2 (enExample)
EP (2) EP3617230A1 (enExample)
JP (2) JP7515461B2 (enExample)
KR (1) KR102866553B1 (enExample)
CN (2) CN112912398B (enExample)
AU (1) AU2019333862B2 (enExample)
BR (1) BR112021003916A2 (enExample)
CA (1) CA3111153A1 (enExample)
IL (1) IL281198A (enExample)
MX (1) MX2021002500A (enExample)
WO (1) WO2020049001A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3552615B8 (en) 2014-07-16 2022-03-02 Transgene Oncolytic virus for expression of immune checkpoint modulators
TW202321458A (zh) * 2021-09-22 2023-06-01 瑞典商生物創新國際公司 新穎抗體組合及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0606217B2 (en) 1991-06-27 2008-12-03 Bristol-Myers Squibb Company Ctl4a receptor, fusion proteins containing it and uses thereof
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
HRP20130077A2 (hr) 1998-12-23 2013-07-31 Pfizer Inc. Humana monoklonalna protutjela za ctla-4
CN102766210B (zh) 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
ES2611975T3 (es) 2006-06-20 2017-05-11 Transgene S.A. Procedimiento para producir poxvirus y composiciones de poxvirus
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
US8012738B2 (en) 2007-05-14 2011-09-06 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
BRPI0820576B1 (pt) 2007-11-19 2021-10-19 Transgène S.A. Uso de um poxvírus oncolítico compreendendo um gene i4l e/ou f4l defectivo ou uma composição compreendendo o mesmo
EP2240573A4 (en) 2008-02-12 2011-08-31 Sanofi Pasteur Ltd METHODS OF USING ION EXCHANGE CHROMATOGRAPHY AND DIFFUSION EXCLUSION CHROMATOGRAPHY FOR PURIFYING POXVIRUS
NZ596595A (en) 2009-05-12 2013-05-31 Transgene Sa Method for orthopoxvirus production and purification
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
ES2813413T3 (es) 2011-08-05 2021-03-23 Sillajen Biotherapeutics Inc Métodos y composiciones para la producción de virus vaccina
US9789182B2 (en) 2012-10-23 2017-10-17 Bristol-Myers Squibb Company Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
EP3552615B8 (en) * 2014-07-16 2022-03-02 Transgene Oncolytic virus for expression of immune checkpoint modulators
US10196445B1 (en) * 2015-03-17 2019-02-05 Bristol-Myers Squibb Company Ipilimumab variant with enhanced ADCC
SI3389699T1 (sl) * 2015-12-15 2024-07-31 OncoC4, Inc. Himerna in humanizirana monoklonska protitelesa proti humanemu ctla4 in uporabe le - teh
WO2017120612A1 (en) * 2016-01-10 2017-07-13 Modernatx, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
NL2017270B1 (en) * 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
FI3551660T3 (fi) 2016-12-07 2023-12-11 Agenus Inc Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
AU2017414149B2 (en) * 2017-05-19 2025-05-15 Wuxi Biologics (Shanghai) Co., Ltd. Novel monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)

Similar Documents

Publication Publication Date Title
JP6847037B2 (ja) 抗cd73抗体とa2a受容体阻害薬とを含む併用治療薬及びその使用
JP2023115329A (ja) 細胞傷害誘導治療剤
EP4214240B1 (en) Anti-ccr8 antibodies
US20230096030A1 (en) Bispecific antibodies against cd9 and cd7
EA034921B1 (ru) Модуляция стимулирующих и нестимулирующих миелоидных клеток
CN112703012A (zh) 治疗癌症的方法
KR20180012864A (ko) Cd38과 특이적으로 결합하는 항체에 의한 고형 종양의 면역 조절 및 치료
KR20210075090A (ko) Gm-csf 길항제를 이용한 면역요법-관련 독성의 치료 방법
CN116096756A (zh) 针对ilt2的抗体及其用途
JP2026076334A (ja) グリピカン3を標的とするキメラ抗原受容体を用いて癌を治療する組成物及び方法
CN114258401B (zh) 对cd38具有特异性的抗体及其用途
US20210230262A1 (en) Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
CN119317643A (zh) 靶向新型肿瘤特异性抗原的骨髓病症和急性白血病的治疗
TW202515608A (zh) Il—18bp拮抗抗體及其於癌症治療之單一療法及組合療法的用途
JP2022512544A5 (enExample)
JP2024534550A5 (enExample)
CN113748132B (zh) 抗trem1抗体和相关方法
CN119161482A (zh) 新颖抗体和核苷酸序列及其用途
RU2021108970A (ru) Новые антитела и нуклеотидные последовательности и их применение
CN114616245B (zh) 一种抗cd38的抗体及其用途
CN116178546B (zh) 一种多功能重组抗体及其制备方法和应用
TWI920354B (zh) 抗ccr8抗體
CN115724979B (zh) 一种多功能重组抗体及其制备方法和应用
CN115466329B (zh) 一种抗pd-1人源化抗体及其应用
CN114127118B (zh) 一种分离的抗原结合蛋白及其应用